Definition and epidemiology
Basal cell carcinoma is a malignant neoplasm derived from basal cells of the epidermis and hair follicles. It is the most common cancer in humans overall, far outnumbering squamous cell carcinoma and melanoma combined.
- Peak incidence in adults over 50-60 years, but incidence is rising in younger patients due to tanning and outdoor sun exposure.
- Fitzpatrick skin types I-II (fair skin, light eyes, red/blonde hair) are at highest risk.
- Male predominance historically, though the gap is narrowing with changing sun-exposure patterns.
- Incidence correlates with cumulative UV exposure and proximity to the equator (higher UV index).
- Lifetime risk in fair-skinned populations is substantial; many patients develop multiple primary BCCs over their lifetime.
- Most common human cancer; strongly linked to cumulative UV exposure.
- PTCH1 mutation causing hedgehog pathway activation is the key molecular driver.
- Nodular subtype: pearly papule with telangiectasias and rolled border.
- Metastasis is extremely rare despite local invasiveness.
- Gorlin syndrome = multiple BCCs + odontogenic keratocysts + skeletal abnormalities (PTCH1 germline mutation).
- Mohs surgery preferred for high-risk facial lesions and morpheaform subtype.
- Vismodegib/sonidegib are hedgehog pathway inhibitors used for advanced/metastatic disease.
- Histology hallmark: basaloid cells with peripheral palisading and stromal retraction artifact.
Etiology and risk factors
Chronic cumulative ultraviolet (UV) radiation exposure is the dominant etiologic factor, acting through DNA damage and activation of the hedgehog signaling pathway.
- UV radiation: chronic sun exposure (UVB mainly), tanning bed use.
- Fair skin phenotype: Fitzpatrick I-II, light eyes, freckling, poor tanning ability.
- Age: risk increases steadily with age due to cumulative UV exposure.
- Immunosuppression: transplant recipients, chronic immunosuppressive therapy.
- Prior radiation therapy to the skin.
- Arsenic exposure.
- Genetic syndromes: basal cell nevus syndrome (Gorlin syndrome, PTCH1 mutation, autosomal dominant) causes multiple BCCs at a young age along with jaw keratocysts and skeletal anomalies; xeroderma pigmentosum impairs DNA repair and markedly increases risk.
- Personal history of BCC is itself a strong risk factor for additional lesions.
Pathophysiology
BCC arises from pluripotent cells in the basal layer of the epidermis and the outer root sheath of hair follicles. The central molecular driver is dysregulated activation of the hedgehog signaling pathway, most commonly through loss-of-function mutations in the tumor suppressor gene PTCH1 (patched homolog 1), which normally inhibits the Smoothened (SMO) receptor. Loss of PTCH1 function (or activating SMO mutations) leads to constitutive hedgehog pathway activation, uncontrolled GLI transcription factor activity, and unchecked basal keratinocyte proliferation.
UV radiation induces these mutations directly through pyrimidine dimer formation and also contributes a secondary mutational signature in TP53, impairing apoptosis of damaged cells. Unlike squamous cell carcinoma, BCC grows slowly and invades locally along tissue planes (nerves, cartilage, bone) rather than metastasizing, because tumor cells remain dependent on the surrounding dermal stroma for survival (stromal dependence), which limits their ability to survive independently at distant sites.
Clinical features
Approximately 80% of BCCs occur on the head and neck, particularly sun-exposed areas like the nose, forehead, and ears.
Nodular BCC (most common subtype)
- Pearly or translucent papule or nodule
- Rolled, raised border
- Overlying telangiectasias
- Central ulceration may develop ("rodent ulcer")
- Does not heal, may bleed with minor trauma
Superficial BCC
- Erythematous, scaly, well-demarcated patch or plaque
- Often on trunk or extremities
- Can mimic eczema or psoriasis
Morpheaform (sclerosing) BCC
- Indurated, scar-like, flesh-colored plaque
- Ill-defined borders, more aggressive local behavior
- Higher risk of subclinical extension and recurrence
Pigmented BCC
- Resembles nodular BCC but with brown/black pigmentation
- Can be mistaken for melanoma
All subtypes share the hallmark of a persistent, non-healing skin lesion in a sun-exposed area.
Diagnosis
Diagnosis requires histopathologic confirmation; clinical appearance alone is suggestive but not definitive.
- Dermoscopy can support clinical suspicion (arborizing telangiectasias, blue-gray ovoid nests, ulceration).
- Skin biopsy (shave, punch, or excisional) is required for definitive diagnosis and subtyping.
- Histology shows nests of basaloid cells with peripheral palisading nuclei and surrounding stromal retraction artifact.
- Subtype on biopsy (nodular vs superficial vs morpheaform/infiltrative) guides treatment choice, since infiltrative and morpheaform subtypes carry higher recurrence risk and often need wider margins or Mohs surgery.
- Imaging (CT/MRI) is reserved for large, deeply invasive, or recurrent tumors suspected of bone or deep structure involvement; it is not needed for typical lesions.
Differential diagnosis
- Squamous cell carcinoma: often more keratotic, scaly, faster growing, higher metastatic potential.
- Melanoma: especially for pigmented BCC; asymmetry, irregular borders, color variation favor melanoma.
- Seborrheic keratosis: waxy, "stuck-on" appearance, benign.
- Actinic keratosis: rough, scaly, precancerous but not invasive.
- Psoriasis or eczema: can mimic superficial BCC; lack of response to topical steroids should prompt biopsy.
- Molluscum contagiosum: umbilicated papule, usually in different age groups/settings.
- Sebaceous hyperplasia: benign yellowish papules, usually multiple, no ulceration.
Management
Treatment choice depends on tumor subtype, size, location, and recurrence risk (low-risk vs high-risk lesions per major guideline bodies such as NCCN and European consensus).
Surgical options (preferred for most lesions)
- Surgical excision with margins (typically 4 mm margins for low-risk lesions): standard first-line treatment.
- Mohs micrographic surgery: preferred for high-risk lesions (morpheaform/infiltrative subtype, recurrent tumors, lesions on face/eyelids/nose/ears, large size) because it allows complete margin control while sparing tissue.
- Curettage and electrodesiccation: option for small, low-risk, superficial or nodular BCCs on trunk/extremities.
- Cryotherapy: for select superficial, low-risk lesions when surgery is not feasible.
Non-surgical options
- Topical imiquimod or topical 5-fluorouracil: approved for superficial BCC in low-risk areas; lower cure rates than surgery.
- Photodynamic therapy: alternative for superficial BCC.
- Radiation therapy: for patients who are poor surgical candidates or as adjuvant therapy for high-risk features.
Advanced/metastatic or locally destructive disease
- Hedgehog pathway inhibitors (vismodegib, sonidegib): targeted oral agents for locally advanced or metastatic BCC not amenable to surgery or radiation.
- Immunotherapy (anti-PD-1, e.g., cemiplimab) is an option for advanced disease progressing on hedgehog inhibitors, per evolving guideline updates.
Follow-up
- Regular skin surveillance is recommended for life given high recurrence and new primary tumor risk; typical interval is every 6-12 months, individualized by risk.
Complications and prognosis
Prognosis is excellent; BCC has one of the lowest cancer-related mortality rates of any malignancy because metastasis is rare (well under 1% of cases).
- Local tissue destruction: untreated or neglected lesions can invade cartilage, bone, and deep structures, especially on the face, causing significant disfigurement (historical term "rodent ulcer").
- Recurrence: higher with morpheaform/infiltrative subtypes, incomplete excision, or high-risk anatomic locations (central face, ears, periorbital area).
- Multiple primary tumors: patients with one BCC have substantially increased risk of developing additional BCCs over time, warranting lifelong surveillance.
- Metastasis: exceedingly rare, but when it occurs it is typically with long-standing, neglected, or very large tumors, and carries a poor prognosis.
- Overall, early detection and treatment nearly always result in cure.
BCC = "Pearly, Pink, Papule with Prominent vessels" (the 4 P's): Pearly surface, Pink/translucent color, Papule/nodule morphology, Prominent telangiectatic vessels.
Practice questions
1. A 68-year-old man with fair skin and a history of frequent outdoor work presents with a slowly enlarging, shiny bump on his nose that bleeds occasionally when he shaves. On exam there is a 6 mm pearly papule with a rolled border and overlying fine telangiectasias. Which of the following is the most likely diagnosis?
2. A 5-year-old boy presents with multiple basal cell carcinomas on the trunk, a broad forehead, and jaw cysts found incidentally on dental imaging. Genetic testing reveals a germline mutation. Which gene is most likely affected?
3. A 72-year-old woman has a biopsy-proven morpheaform basal cell carcinoma on her left nasal ala measuring 1.2 cm with poorly defined clinical borders. Which treatment approach is most appropriate to minimize recurrence while preserving surrounding tissue?
Frequently asked questions
What causes basal cell carcinoma?
Basal cell carcinoma is caused primarily by cumulative ultraviolet radiation exposure, which damages DNA in basal keratinocytes and activates the hedgehog signaling pathway, most often through PTCH1 gene mutations. Additional risk factors include fair skin type, older age, immunosuppression, prior radiation exposure, arsenic exposure, and inherited syndromes like Gorlin syndrome.
What are the first symptoms of basal cell carcinoma?
The earliest sign is usually a small, slow-growing, pearly or translucent bump on sun-exposed skin, often with visible tiny blood vessels (telangiectasias) on its surface. It may be mistaken for a pimple or scar because it does not heal and can bleed easily after minor trauma. Some lesions instead appear as a flat, scaly, reddish patch.
How is basal cell carcinoma diagnosed?
Diagnosis is confirmed with a skin biopsy, which shows characteristic nests of basaloid tumor cells with peripheral palisading under the microscope. A dermatologist typically first examines the lesion with dermoscopy to assess suspicious features, then performs a shave or punch biopsy to confirm the diagnosis and determine the histologic subtype before planning treatment.
Is basal cell carcinoma curable?
Yes, basal cell carcinoma is highly curable, especially when detected and treated early, with cure rates exceeding 95% after appropriate surgical treatment. It almost never spreads to other organs, though it can grow locally into surrounding tissue if neglected. Patients remain at increased risk for new BCCs and need ongoing skin checks.
Basal cell carcinoma vs squamous cell carcinoma — what is the difference?
Basal cell carcinoma arises from basal keratinocytes, grows slowly, rarely metastasizes, and typically looks like a pearly papule with telangiectasias, while squamous cell carcinoma arises from keratinizing cells, tends to be more scaly or crusted, grows faster, and carries a meaningfully higher risk of metastasis, particularly in high-risk locations or immunosuppressed patients.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: C44
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.